Back to top
more

Rigel Pharmaceuticals (RIGL)

(Delayed Data from NSDQ)

$10.53 USD

10.53
71,571

0.00 (0.00%)

Updated Jul 24, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (103 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Earnings Preview: Rigel Pharmaceuticals (RIGL) Q2 Earnings Expected to Decline

by Zacks Equity Research

Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: GILD, MRNA Give Coronavirus Treatment Updates & More

by Zacks Equity Research

The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.

Rigel Pharmaceuticals (RIGL) Looks Good: Stock Adds 9.7% in Session

by Zacks Equity Research

Rigel Pharmaceuticals (RIGL) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Aclaris Gets FDA Nod to Start Investigator-led Coronavirus Study

by Zacks Equity Research

Aclaris (ACRS) announces that it supports an IND application to evaluate its oral investigational MK2 inhibitor compound, ATI-450, in hospitalized patients with COVID-19.

Rigel Pharmaceuticals (RIGL) Q1 Earnings Match Estimates

by Zacks Equity Research

Rigel (RIGL) delivered earnings and revenue surprises of 0.00% and -2.08%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Rigel Pharmaceuticals (RIGL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Rigel Pharmaceuticals (RIGL) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Rigel (RIGL) delivered earnings and revenue surprises of 9.09% and -2.38%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Aclaris' MK2 Inhibitor Shows Encouraging Data in Phase I

by Zacks Equity Research

Aclaris (ACRS) announces favorable preliminary data from the phase I study on its investigational candidate ATI-450, presently being developed for treating immuno-inflammatory diseases. Stock rises.

Tyme Initiates Dosing in Pivotal Pancreatic Cancer Study

by Zacks Equity Research

Tyme (TYME) is evaluating its lead cancer candidate, SM-88, as third-line treatment for metastatic pancreatic cancer in a pivotal study.

Rigel Gets Positive CHMP Review for Thrombocytopenia Drug

by Zacks Equity Research

The CHMP advocates Rigel's (RIGL) marketing approval for Tavalisse to treat chronic immune thrombocytopenia in Europe.

Sanghamitra Saha headshot

Pharma Sector Tops in October: Best ETFs & Stocks

by Sanghamitra Saha

Pharma sector wins in October, making these ETFs and stocks winners.

Rigel Pharmaceuticals (RIGL) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rigel (RIGL) delivered earnings and revenue surprises of 36.36% and 28.19%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Rigel Pharmaceuticals (RIGL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Rigel (RIGL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aclaris Divests Rhofade to EPI Health for $55M, Shares Up

by Zacks Equity Research

Aclaris (ACRS) divests worldwide rights to its rosacea drug, Rhofade, to privately-held EPI Health as part of its restructuring program.

Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rigel (RIGL) delivered earnings and revenue surprises of 14.29% and 12.56%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

What's in the Cards for Bausch Health (BHC) in Q2 Earnings?

by Zacks Equity Research

Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q2 results on Aug 6.

Is a Beat in the Cards for Regeneron (REGN) Q2 Earnings?

by Zacks Equity Research

Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports second-quarter 2019 results.

Rigel Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Rigel Pharmaceuticals, Inc. (RIGL) has been struggling lately, but the selling pressure may be coming to an end soon.

Dova Receives Approval for Doptelet in Europe, Stock Up

by Zacks Equity Research

Dova Pharmaceuticals (DOVA) announces approval of its thrombocytopenia drug, Doptelet, in Europe for patients with chronic liver disease.

Rigel Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Rigel Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

Rigel Initiates Enrollment in Pivotal Blood Disorder Study

by Zacks Equity Research

Rigel (RIGL) enrolls first patient in a pivotal label expansion study evaluating its approved drug, Tavalisse, in patients with antibody autoimmune hemolytic anemia.

Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rigel (RIGL) delivered earnings and revenue surprises of 15.38% and 5.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Do Options Traders Know Something About Rigel Pharmaceuticals (RIGL) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Rigel Pharmaceuticals (RIGL) stock based on the movements in the options market lately.

Implied Volatility Surging for Rigel Pharmaceuticals (RIGL) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Rigel Pharmaceuticals (RIGL) stock based on the movements in the options market lately.

Rigel Pharmaceuticals (RIGL) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rigel (RIGL) delivered earnings and revenue surprises of 12.50% and 38.41%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?